Rethinking TREM2 as a target for Alzheimer's disease after the INVOKE-2 trial failure. Colonna M, Holtzman DM. Nat Med 2025 Jul 2. doi: 10.1038/s41591-025-03816.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Colonna M, Holtzman DM. Rethinking TREM2 as a target for Alzheimer's disease after the INVOKE-2 trial failure. Nat Med 2025 Jul 2. doi: 10.1038/s41591-025-03816.
PMID: 40603729